Evidence map›Paper›PMID 33625546›Full record

ArticleApplied microbiology and biotechnology2021

Micromonospora species from rarely-exploited Egyptian habitats: chemical profile, antimicrobial, and antitumor activities through antioxidant property.

Mohamed S Nafie, Noha M Awad, Hend M Tag, Ibrahim M Abd El-Salam, Mohamed K Diab, Sahar A El-Shatoury

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. In Vitro Antitumor Activity of Endophytic and Rhizosphere Gram-Positive Bacteria fromInternational journal of environmental research and public health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Mohamed S NafieChemistry Department, Faculty of Science, Suez Canal University, Ismailia, 41522, Egypt. mohamed_nafie@science.suez.edu.eg.ORCID http://orcid.org/0000-0003-4454-6390
Noha M AwadDepartment of Botany and Microbiology, Faculty of Science, Suez Canal University, Ismailia, 41522, Egypt.
Hend M TagZoology Department, Faculty of Sciences, Suez Canal University, Ismailia, 41522, Egypt.
Ibrahim M Abd El-SalamNational Cancer Institute, Cairo University, Cairo, Egypt.
Mohamed K DiabPest Physiology Department, Plant Protection Research Institute, Agricultural Research Center, Zagazig, 12311, Egypt.
Sahar A El-ShatouryDepartment of Botany and Microbiology, Faculty of Science, Suez Canal University, Ismailia, 41522, Egypt. sahar_hassan@science.suez.edu.eg.
Suez Canal University · EGAgricultural Research Center · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of new anticancer agents with a selective action mechanism has become a significant scientific challenge, especially as cancers remain the world's leading cause of death. Actinobacteria and its bioactive compounds have recently become a promising perspective alternative to cancer therapy. In this study, some extracted metabolites of Micromonospora exhibited potent antimicrobial with microbial inhibition zone ≥ 7 mm, and cytotoxic activities against MCF-7 and HepG2 cell lines with promising activities ≥ 85%. Additionally, treatment of DENA/CCl4 rats with the strain Micromonospora sp1 has induced a substantial amelioration of the liver functions, enhancing liver architecture near normal and antioxidant properties through elevation of antioxidant enzyme levels. So that these preliminary results can provide metabolites from Micromonospora sp1 as an anti-liver cancer therapy. Finally, we introduced the chemical profiling of Micromonospora sp1 metabolic extract by LC-QTOF-MS-MS technique, where eight compounds with reported antioxidant property anti-liver cancer activity were targeted, validated as iNOS inhibitor through molecular docking studies. The findings in this study can be a significant step towards studying natural bioactive products produced by Micromonospora spp. as agents for anti-liver cancer. KEY POINTS: • Metabolites of Micromonospora strain from unexploited Egyptian habitats were investigated with LC/MS library-based chemical profile and molecular docking studies as iNOS inhibitors. • Some Micromonospora strains exhibited potent antimicrobial with microbial inhibition zone ≥ 7 mm, and cytotoxic activities against MCF-7 and HepG2 cell lines with promising activities ≥ 85%. • Micromonospora extract exhibited anti-liver cancer activity in vivo through the antioxidant property by inhibiting the liver cancer biomarkers (LDH and AFP) and enhancing other biochemical parameters.

Indexed as

MicromonosporaAnimalsAntioxidantsEcosystemEgyptMolecular Docking SimulationRatsAntioxidantsAnti-liver cancerAnti-microbialDockingLC/MSMicromonospora metabolites

Identifiers

PMID33625546
OpenAlexW3130089273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.